ATAI Life Sciences NV (9VC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ATAI Life Sciences NV (9VC) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-23.26 Million ≈ $-27.19 Million USD) by net assets (€159.91 Million ≈ $186.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 9VC company net worth for the company's overall valuation and market capitalisation.
ATAI Life Sciences NV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ATAI Life Sciences NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ATAI Life Sciences NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ATAI Life Sciences NV ranked by their cash flow conversion efficiency. Explore how high is ATAI Life Sciences NV's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Premier Investments Ltd
AU:PMV
|
0.041x |
|
Omai Gold Mines Corp
V:OMG
|
-0.071x |
|
Navigator Holdings Ltd
NYSE:NVGS
|
0.042x |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
0.014x |
|
Jilin Chemical Fibre Co Ltd
SHE:000420
|
0.011x |
|
Dar Global Plc
LSE:DAR
|
0.112x |
|
WIN Semiconductors
TWO:3105
|
-0.020x |
|
Rusta AB (publ)
ST:RUSTA
|
0.316x |
Annual Cash Flow Conversion Efficiency for ATAI Life Sciences NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of ATAI Life Sciences NV from 2019 to 2024. View ATAI Life Sciences NV (9VC) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €116.55 Million ≈ $136.26 Million |
€-82.44 Million ≈ $-96.38 Million |
-0.707x | -105.43% |
| 2023-12-31 | €244.32 Million ≈ $285.63 Million |
€-84.12 Million ≈ $-98.34 Million |
-0.344x | +12.41% |
| 2022-12-31 | €265.77 Million ≈ $310.71 Million |
€-104.47 Million ≈ $-122.13 Million |
-0.393x | -139.88% |
| 2021-12-31 | €385.96 Million ≈ $451.23 Million |
€-63.25 Million ≈ $-73.94 Million |
-0.164x | +24.74% |
| 2020-12-31 | €95.37 Million ≈ $111.50 Million |
€-20.77 Million ≈ $-24.28 Million |
-0.218x | -65.51% |
| 2019-12-31 | €59.64 Million ≈ $69.72 Million |
€-7.85 Million ≈ $-9.17 Million |
-0.132x | -- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more